pathogen
safeti
bloodplasmaderiv
product
histor
subject
signific
concern
medic
commun
measur
donor
select
blood
screen
contribut
increas
safeti
product
pathogen
transmiss
still
occur
reason
includ
lack
sensitivityspecif
current
screen
method
lack
reliabl
screen
test
pathogen
eg
prion
fact
mani
potenti
harm
infecti
agent
routin
screen
method
purificationinactiv
bloodplasmaderiv
product
develop
order
reduc
residu
risk
low
concentr
pathogen
necessarili
impli
low
level
risk
patient
overal
challeng
minimis
risk
remain
review
aim
discuss
variabl
level
pathogen
risk
describ
current
screen
method
use
preventdetect
presenc
pathogen
blood
plasmaderiv
product
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
b
l
r
e
may
contain
infecti
agent
effect
reduc
rate
pathogen
transmiss
may
result
unnecessari
wastag
bloodplasmaderiv
product
sinc
recombin
clot
factor
deriv
blood
plasma
present
minim
risk
pathogen
transmiss
particularli
third
gener
factor
contact
blood
plasmaderiv
compon
whatsoev
therefor
consid
safer
use
plasmaderiv
clot
factor
concentr
howev
concern
use
recombin
clot
factor
may
associ
increas
rate
inhibitor
format
patient
regularli
receiv
product
anoth
factor
may
influenc
overal
clinic
assess
patient
risk
recombin
clot
factor
avail
treatment
haemophilia
fviii
b
fix
factor
viixiii
defici
plasmaderiv
concentr
avail
clot
factor
includ
von
willebrand
factor
fibrinogen
vitamin
k
depend
clot
factor
case
fresh
frozen
plasma
cryoprecipit
avail
replac
therapi
eg
factor
v
defici
ideal
plasma
plasmaderiv
product
would
complet
replac
recombin
product
order
minimis
risk
pathogen
transmiss
howev
alway
possibl
recent
articl
comprehens
review
pathogen
safeti
plasmaderiv
recombin
clot
factor
review
examin
potenti
transmiss
infecti
agent
might
present
bloodplasmaderiv
product
use
treat
haemostat
disord
focu
ident
agent
screen
procedur
use
detect
well
limit
screen
current
unmet
need
field
pathogen
safeti
bloodplasmaderiv
product
also
discuss
pubm
databas
interrog
januari
present
use
search
string
bleed
disord
haemophilia
pathogen
blood
safeti
search
term
viru
bacteria
haemorrhag
disord
von
willebrand
diseas
fvii
defici
fxiii
defici
ad
search
yield
addit
pertin
result
bibliographi
review
also
use
identifi
relev
refer
individu
search
conduct
inform
specif
pathogen
inform
opinion
also
provid
author
infecti
agent
present
bloodplasmaderiv
product
lesson
past
current
concern
acut
bleed
episod
aris
either
inherit
bleed
disord
eg
haemophilia
von
willebrand
diseas
acquir
defici
haemostat
compon
eg
due
infect
malign
autoimmun
diseas
trauma
surgeri
result
infect
organ
caus
haemorrhag
diseas
eg
ebola
marburg
viru
variou
treatment
option
exist
prevent
treat
acut
bleed
episod
includ
freshfrozen
plasmacryoprecipit
platelet
plasmaderivedrecombin
clot
factor
concentr
use
bloodderiv
recombin
haemostat
product
increas
markedli
recent
year
exemplifi
global
use
factor
viii
product
fig
increas
use
driven
improv
avail
clot
factor
increas
life
expect
peopl
bleed
disord
increas
use
prophylaxi
sever
bleed
disord
decreas
risk
transmiss
infecti
agent
histor
risk
transmiss
infecti
agent
via
blood
plasmaderiv
product
great
concern
medic
commun
risk
reduc
dramat
sinc
implement
stricter
donat
screeningdonor
select
procedur
improv
purif
procedur
fulli
erad
furthermor
implement
pathogen
inactiv
technolog
bloodplasmaderiv
product
reduc
risk
transmiss
known
emerg
pathogen
although
result
variabl
accord
method
use
howev
import
note
patient
risk
highli
depend
circumst
blood
product
collect
handl
use
gener
clinician
assess
level
risk
associ
use
blood
plasmaderiv
product
evalu
factor
patient
characterist
eg
age
immun
statu
geograph
locat
lifestyl
natur
pathogen
eg
physic
characterist
level
virul
chronic
infect
preval
presenc
particular
pathogen
within
bloodplasmaderiv
product
may
pose
signific
threat
specif
patient
group
eg
elderli
immunocompromis
low
risk
gener
popul
eg
hev
clinic
assess
risk
base
varieti
factor
virolog
assess
risk
base
sole
presenc
absenc
pathogen
presenc
pathogen
impli
possibl
infect
pathogenfre
product
describ
entir
riskfre
adopt
virolog
approach
ie
discard
product
larg
number
pathogen
agent
includ
virus
protozoan
parasit
prion
transmit
via
bloodplasmaderiv
product
capabl
caus
diseas
human
tabl
presenc
virus
plasmaderiv
product
becam
concern
patient
sever
haemophilia
becam
infect
human
immunodefici
viru
concern
continu
discoveri
patient
treat
plasmaderiv
product
prior
becom
infect
hepat
c
viru
hcv
current
donor
select
screen
practic
improv
abil
detect
reduc
presenc
pathogen
bloodplasmaderiv
product
exampl
residu
risk
transfusiontransmit
infect
tti
hivhbvhcv
fallen
near
less
per
million
transfus
unit
despit
success
howev
residu
risk
still
remain
pathogen
agent
shown
tabl
supplementari
appendix
form
exhaust
list
mani
microorgan
normal
nonpathogen
potenti
caus
diseas
respond
chang
biolog
environ
transfus
immunosuppress
patient
addit
still
risk
new
emerg
pathogen
may
enter
blood
suppli
tabl
standard
assay
commonli
use
blood
screen
nucleic
acid
amplif
technolog
nat
immunoassay
detect
antibodi
andor
antigen
immunoassay
frequent
use
screen
purpos
multipl
sampl
process
togeth
may
yield
semiquantit
result
nat
assay
allow
earlier
pathogen
detect
immunoassay
also
costli
complex
assay
select
gener
determin
level
accuracyspe
requir
factor
resourc
avail
eg
staff
infrastructur
assay
complex
cost
consider
eg
consum
must
also
consid
assay
blood
donat
screen
mandatori
particularli
europ
north
america
world
health
organ
recommend
whole
blood
blood
process
apheresi
undergo
pathogen
screen
use
clinic
manufactur
purpos
screen
hbv
hcv
treponema
pallidum
subspeci
pallidum
pallidum
caus
agent
syphili
strongli
advis
world
feder
hemophilia
wfh
suggest
countri
carri
individu
routin
screen
pathogen
base
epidemiolog
inform
region
eg
trypanosoma
cruzi
wfh
also
acknowledg
posit
impact
hiv
hbv
hcv
screen
global
blood
safeti
recommend
screen
test
implement
whenev
possibl
detail
serolog
test
carri
individu
donor
plasma
nat
test
plasma
minipool
shown
tabl
recommend
minimum
evalu
sensitivityspecif
level
assay
use
blood
donat
screen
higher
howev
assay
fulfil
criteria
sensit
specif
level
vari
accord
assay
type
type
microorgan
test
see
tabl
detail
therefor
gener
advic
screen
donat
blood
high
standard
possibl
earli
stage
infect
hiv
hbv
hcv
viraemia
occur
host
bloodstream
variabl
level
viral
antigen
may
appear
time
dnarna
often
becom
detect
sever
week
later
specif
antibodi
measur
week
infect
time
initi
infect
appear
detect
paramet
infect
eg
viral
nucleic
acidantigen
antibodi
known
window
period
hiv
screen
blood
presenc
use
combin
antigenantibodi
assay
advis
combin
hiv
ag
antibodi
allow
earlier
detect
infect
perform
nat
test
mandatori
mani
countri
reduc
window
period
around
day
hbv
major
diagnost
laboratori
focu
detect
hbsag
first
detect
serolog
marker
infect
howev
risk
hbsag
concentr
may
declin
undetect
level
cours
infect
yield
fals
neg
result
screen
antibodi
hbc
conserv
approach
identifi
potenti
expos
donor
identifi
individu
ever
immunolog
experienc
type
hbv
infect
either
current
chronic
resolv
may
experi
viral
reactiv
lifetim
particularli
condit
immunosuppress
howev
assay
measur
hbc
antibodi
rel
nonspecif
alway
correl
presenc
hbv
viru
plasma
also
exclud
possibl
donor
test
posit
antihbc
puls
recurr
viru
replic
result
presenc
low
level
hbvdna
plasma
reason
nation
transfus
servic
alway
routin
screen
donat
antihbc
nat
assay
carri
use
restrict
potenti
low
level
viral
dna
combin
use
hbsag
screen
test
nat
assay
reduc
window
period
detect
hbv
infect
approxim
day
mutant
hbv
strain
escap
variant
also
consid
may
occasion
escap
serolog
detect
although
detect
nat
assay
hbvvariant
rare
therefor
like
enter
contamin
blood
suppli
difficult
detect
summari
screen
blood
suppli
presenc
hbv
effect
optim
screen
system
yet
defin
hcv
hcv
recent
chronic
infect
detect
screen
blood
presenc
hcv
antigen
hcv
antibodi
antihcv
seroconvers
occur
approxim
week
postinfect
howev
steadi
improv
screen
technolog
includ
adopt
nat
assay
reduc
window
period
approxim
week
hiv
nat
assay
use
detect
earli
infect
although
issu
low
viral
rna
concentr
persist
endem
region
rare
other
therefor
screen
conduct
geograph
atrisk
basi
presenc
viru
mostli
infer
detect
virusspecif
antibodi
use
sensit
immunoassay
instanc
screen
involv
detect
nonspecif
nontreponem
specif
treponem
antibodi
nat
assay
gener
use
specif
antibodi
test
identifi
individu
ever
expos
bacterium
may
continu
yield
posit
result
ten
year
follow
initi
infect
nonspecif
test
eg
vdrl
cardiolipin
test
primarili
use
identifi
donor
may
activ
infect
sinc
pallidum
heatsensit
readili
withstand
extend
storag
low
temperatur
storag
three
day
suffici
render
pathogen
noninfecti
howev
blood
compon
eg
platelet
store
temperatur
around
present
risk
pallidum
persist
therefor
screen
antibodi
organ
recommend
blood
screen
pathogen
appropri
accord
geograph
locat
season
activ
vector
also
patient
risk
factor
current
viral
pathogen
interest
mosquitoborn
flaviviru
west
nile
viru
wnv
confirm
transmit
via
transfus
immedi
screen
polici
put
place
usa
order
reduc
risk
transmiss
polici
includ
deferr
individu
display
symptom
infect
quarantin
plasma
collect
period
high
mosquito
activ
wnv
preval
rapid
developmentus
wnvspecif
nat
serolog
assay
measur
highli
effect
caus
signific
reduct
number
confirm
case
wnv
transfusionrel
transmiss
howev
wnv
outbreak
still
occur
within
america
indic
potenti
need
season
blood
screen
wnv
wnv
outbreak
also
occur
europ
includ
itali
greec
prompt
implement
season
blood
screen
procedur
affect
region
countri
anoth
mosquitoborn
pathogen
could
potenti
pose
risk
transfus
safeti
although
date
report
transfusionrel
transmiss
viru
rare
mutat
form
chikungunya
viru
respons
sever
epidem
past
decad
spread
reunion
island
indian
ocean
itali
caribbean
area
viru
may
detect
blood
donor
nat
help
reduc
level
transmiss
risk
also
concern
possibl
parvoviru
blood
suppli
preval
worldwid
seropreval
blood
donor
vari
usa
europ
africa
asia
risk
parvoviru
transmiss
higher
unit
blood
pool
eg
creat
batch
clot
factor
concentr
albumin
etc
individu
bleed
disord
higher
risk
infect
dna
detect
clot
factor
concentr
recent
german
studi
anoth
studi
found
popul
receiv
bloodderiv
product
time
like
display
antibodi
popul
receiv
blood
product
lack
lipid
envelop
render
highli
resist
method
pathogen
inactiv
screen
blood
donat
dna
current
routin
mani
manufactur
process
plasma
screen
absenc
dna
order
reduc
risk
transmiss
given
preval
differ
popul
difficult
defin
residu
tti
risk
viru
howev
clear
transmiss
risk
exist
trypanosoma
brucei
gambienserhodiens
africa
risk
direct
microscop
visualisationantibodynat
nat
trypanosomesml
nat
trypanosomesml
antibodi
catt
nat
antibodi
catt
nat
continu
next
page
potenti
presenc
hepat
e
viru
hev
blood
bloodderiv
product
relev
current
seem
discrep
number
hevrna
posit
blood
donat
europ
rang
germani
donat
netherland
low
number
confirm
case
hepat
e
blood
transfus
recipi
one
confirm
case
uk
one
franc
two
germani
indic
subject
hev
infect
pathogen
need
investig
also
debat
necess
introduc
screen
blood
presenc
hev
viru
current
screen
uk
european
countri
although
one
studi
english
donor
found
hev
widespread
donat
within
donor
popul
sinc
infect
viru
harm
immunocompromis
individu
potenti
need
introduc
hev
screen
consid
residu
risk
tti
hbv
hcv
hiv
hev
select
countri
given
tabl
despit
recent
advanc
method
detect
prion
singl
method
develop
screen
test
blood
although
sever
method
anim
model
show
great
promis
human
protocol
evalu
bloodbas
test
suitabl
diagnosi
variant
creutzfeldtjakob
diseas
vcjd
establish
test
yet
appear
satisfi
requir
sensit
specif
report
far
bloodbas
diagnost
test
vcjd
claim
assay
sensit
specif
symptomat
patient
potenti
applic
screen
test
detect
asymptomat
vcjd
infect
recent
investig
current
strategi
confirm
posit
screen
result
although
protein
misfold
cyclic
amplif
techniqu
recent
shown
yield
posit
result
buffi
coatwhit
blood
cell
sampl
small
number
patient
vcjd
extens
use
blood
donor
select
test
alway
guarante
safe
product
test
insuffici
sensit
fals
neg
may
occur
altern
test
suffici
specif
eg
antihbc
assay
hbv
may
caus
fals
posit
result
lead
unnecessari
decreas
number
clot
product
avail
torqu
tenoviru
ttv
exampl
test
specif
issu
viru
exist
variou
diverg
form
distinct
genotyp
identifi
thu
far
sinc
ttv
often
detect
healthi
individu
associ
particular
diseas
routin
screen
viru
consid
necessari
even
test
excel
sensitivityspecif
would
contribut
increas
level
safeti
bloodplasmaderiv
product
regard
ttv
insuffici
assay
sensit
remain
rare
potenti
problem
blood
donat
screen
window
period
initi
hbv
hcv
hiv
infect
increas
test
sensit
threshold
need
prevent
hbv
transmiss
via
bloodplasmaderiv
product
blood
transfus
extrem
low
concentr
hbv
eg
copiesml
capabl
viral
transmiss
see
section
antihbc
posit
patient
case
hiv
hcv
even
nat
test
may
alway
suffici
ensur
suffici
high
level
safeti
viru
transmiss
previous
occur
transfus
blood
undetect
level
viraemia
recent
report
highlight
concern
inabl
nat
assay
detect
differ
variant
hiv
least
four
case
presenc
rna
undetect
nat
assay
screen
potenti
put
transfus
recipi
risk
two
falseneg
result
occur
due
genet
mutat
viral
rna
region
target
nat
assay
primer
although
case
overal
figur
avail
specificitysensit
describ
low
medium
high
appropri
catt
card
agglutin
test
trypanosomiasi
idnat
individu
donat
nat
mpnat
minipool
nat
nat
nucleic
acid
test
pcr
polymeras
chain
reaction
pfu
plaqueform
unit
major
case
serolog
yield
posit
result
falseneg
result
avoid
design
nat
assay
target
minimum
two
amplif
region
test
mandatori
germani
hope
sensit
specif
nat
test
continu
improv
case
undetect
infect
may
becom
less
issu
futur
recent
report
suggest
necessari
carri
serolog
screen
multipl
hbv
marker
nat
base
screen
prefer
howev
risk
practic
reli
upon
singl
method
screen
may
lead
higher
incid
falseneg
result
one
case
transfusionassoci
parvoviru
transmiss
donat
blood
screen
presenc
antigen
deem
safe
sinc
antigen
detect
sinc
recipi
subsequ
develop
infect
donat
reanalys
found
contain
dna
report
support
argument
multipl
paramet
test
localis
pathogen
within
blood
may
also
influenc
eas
detect
exampl
wnv
present
higher
level
whole
blood
plasma
viraem
seroposit
donor
situat
revers
viraem
seroneg
donor
display
higher
wnv
level
plasma
whole
blood
also
cellassoci
virus
cmv
less
frequent
transmit
use
leukoreduc
product
indic
virus
less
like
found
bloodplasmaderiv
product
minimum
infect
dose
mid
lowest
number
pathogen
particl
requir
success
infect
host
particular
pathogen
like
reach
whole
blood
bloodderiv
compon
make
use
plasmaderiv
recombin
clot
factor
safest
option
date
studi
attempt
measur
human
mid
valu
gener
determin
viral
concentr
need
infect
particular
percentag
expos
popul
eg
valu
human
infect
dose
popul
refer
hid
often
describ
human
mid
hid
valu
vari
greatli
pathogen
even
physic
similar
also
vari
depend
upon
immun
statu
recipi
immunocompromis
individu
neonat
elderli
greater
risk
infect
healthi
individu
find
preval
immunocompromis
patient
receiv
blood
product
taken
account
impli
need
screen
test
highest
sensit
possibl
impact
transmiss
morbid
mortal
depend
patient
characterist
exampl
although
vast
major
case
cmv
infect
clinic
import
influenc
factor
genet
predisposit
malnutrit
preexist
infect
lead
develop
sever
diseas
nation
screen
programm
current
screen
cmv
standard
nat
assay
exist
may
carri
requir
eg
blood
specif
intend
vulner
recipi
pregnant
women
transplant
patient
opinion
author
serolog
assay
nat
test
use
order
reach
highest
level
safeti
possibl
particularli
case
immunosuppress
patient
well
blood
donat
test
rang
measur
use
increas
pathogen
safeti
bloodand
plasmaderiv
product
includ
donor
select
screen
recipi
vaccin
use
blood
product
purificationinactiv
method
choic
inactiv
method
also
impact
upon
level
risk
questionnair
often
use
attempt
assess
donor
health
statu
potenti
exposur
variou
risk
donor
accept
reject
basi
answer
questionnair
altern
blood
may
put
addit
screen
test
appropri
patient
bleed
disord
vaccin
hav
hbv
european
studi
report
univers
hbv
vaccin
blood
donor
could
costeffect
measur
would
reduc
risk
hbv
transmiss
gener
might
even
remov
necess
gener
hbv
nat
test
howev
would
reduc
risk
pose
hbv
escap
variant
describ
earlier
bloodplasmaderiv
product
typic
undergo
variou
procedur
design
reduc
pathogen
level
although
procedur
effect
pathogen
plasma
donat
undergo
quarantin
approxim
month
prior
fraction
donor
screen
neg
ffp
subject
chromatograph
fraction
solventdeterg
treatment
nanofiltr
andor
heat
inactiv
prolong
product
storag
time
effect
reduc
infect
temperaturesensit
pathogen
pallidum
product
recombin
product
also
follow
strict
protocol
remov
inactiv
virus
might
present
even
though
risk
viral
presenc
minim
although
current
purificationinactiv
techniqu
solventdeterg
treatment
nanofiltr
heat
activ
reduc
risk
pathogen
transmiss
alway
suffici
render
bloodplasmaderiv
product
safe
small
nonenvelop
virus
eg
hav
picornaviru
often
highli
resist
inactiv
procedur
may
still
infecti
plasmaderiv
concentr
presenc
prion
also
concern
attempt
remov
prion
plasmaderiv
product
involv
sever
techniqu
includ
ionexchang
chromatographi
nanofiltr
sever
problem
exist
approach
particular
use
exogen
spike
deriv
prioninfect
brain
homogen
measur
prion
clearanc
may
result
overestim
amount
prion
remov
method
use
estim
reduct
prion
load
ideal
involv
bioassay
measur
infect
develop
field
requir
address
issu
recent
propos
approach
inactiv
infecti
agent
blood
wholeblood
treatment
ultraviolet
uv
light
combin
photosensitis
riboflavin
amotosalen
main
disadvantag
approach
uv
treatment
link
format
neoantigen
may
gener
via
modif
surfac
antigen
platelet
presenc
neoantigen
may
provok
recipi
immun
respons
transfus
uvtreat
platelet
caus
rapidli
clear
circul
approach
pathogen
inactiv
current
use
platelet
effect
need
refin
inactiv
whole
blood
wfh
strongli
recommend
use
plasmaderiv
recombin
product
prefer
cryoprecipit
fresh
frozen
plasma
infecti
load
infecti
human
pathogen
lower
plasmaderiv
product
cryoprecipit
even
lower
recombin
product
european
countri
recombin
product
almost
complet
replac
plasmaderiv
product
use
recombin
product
manufactur
formul
minim
addit
humananimalderiv
materi
greatli
reduc
risk
recipi
exposur
plasmaderiv
infecti
agent
undergon
viru
removalinactiv
process
recombin
product
consid
safe
current
possibl
despit
benefit
use
recombin
product
may
limit
higher
cost
perceiv
problem
inhibitor
format
indic
recombin
factor
concentr
avail
use
inactiv
plasmaderiv
concentr
safer
fresh
frozen
plasma
reduc
risk
advers
effect
hypervolemia
transfusionrel
lung
injuri
trali
hypersensit
minim
risk
approach
would
ensur
patient
receiv
effect
treatment
lowest
possibl
risk
difficult
achiev
practic
term
regulatori
need
differ
european
countri
usual
base
recommend
medic
commun
order
achiev
minim
risk
would
ideal
regul
standardis
mandatori
countri
direct
issu
european
union
commiss
describ
regulatori
requir
safeti
whole
blood
plasma
state
precautionari
measur
collect
process
distribut
use
need
taken
make
appropri
use
scientif
progress
detect
inactiv
elimin
transfus
transmiss
pathogen
agent
howev
rel
safeti
differ
screen
test
product
process
method
discuss
individu
countri
may
adopt
differ
approach
toward
minimis
risk
although
recombin
product
associ
highest
level
pathogen
safeti
higher
cost
develop
product
may
make
expens
healthcar
system
inhibitor
format
also
remain
import
element
concern
plasmaderiv
recombin
product
particularli
regard
fviii
haemophilia
risk
inhibitor
format
shown
greater
recombin
versu
plasmaderiv
factor
viii
concentr
cohort
studi
similar
other
light
consider
avail
advers
reaction
cost
appear
issu
pathogen
safeti
bloodplasmaderiv
product
highli
import
may
limit
factor
respect
overal
patient
safeti
benefit
treatment
hypothet
unsaf
plasmaderiv
product
may
outweigh
risk
neg
outcom
eg
bleed
inhibitor
format
although
suggest
may
clinic
simpler
deal
inhibitor
format
combat
infect
unknown
untreat
pathogen
still
signific
knowledg
gap
area
unmet
need
respect
pathogen
safeti
bloodplasmaderiv
recombin
product
incid
hbv
hcv
hiv
tti
fallen
near
per
million
transfus
unit
industrialis
world
indic
current
donor
select
blood
screen
strategi
posit
impact
blood
safeti
howev
clear
screen
donor
donat
blood
exclud
known
pathogen
elimin
risk
emerg
pathogen
histor
preced
indic
blood
suppli
alway
vulner
contamin
hitherto
nonprevalentunknown
pathogen
risk
accur
gaug
identifi
new
infecti
agent
concern
develop
new
test
detect
also
necessari
clearli
defin
infecti
dose
rang
agent
use
appropri
sensit
test
identif
exampl
suspect
case
vcjd
infect
consider
challeng
remain
develop
screen
confirmatori
test
suffici
sensit
specif
use
clinic
set
within
blood
bank
surveil
peopl
haemophilia
requir
monitor
pathogen
safeti
issu
relat
blood
plasma
product
european
haemophilia
safeti
surveil
system
euhass
began
pharmacovigil
programm
span
european
countri
design
detect
monitor
investig
advers
drug
reaction
report
advers
event
acuteallerg
event
tti
inhibitor
submit
euhass
particip
centr
cumul
patient
clot
factor
data
record
annual
formal
coordin
riskassess
manag
action
plan
addit
task
forc
develop
respond
quickli
emerg
infect
plan
includ
longterm
storag
sampl
produc
batch
retest
case
outbreak
known
recent
emerg
infecti
agent
guidanc
respons
developingperform
test
emerg
pathogen
industri
vs
regulatori
agenc
guidanc
approach
patient
potenti
infect
surveil
strategi
patient
high
risk
would
also
benefici
major
evid
indic
concept
clinic
safeti
bloodplasma
deriv
necessarili
correspond
concept
pathogen
safeti
blood
class
microbi
safe
refer
infecti
agent
known
screen
establish
whether
presenc
undetect
microb
blood
clinic
relev
requir
longterm
detail
studi
also
note
even
though
risk
transmiss
key
detect
virus
hiv
hbv
hcv
via
transfus
fallen
significantli
transmiss
still
occur
gener
balanc
safeti
efficaci
practic
difficult
goal
achievepati
safeti
typic
key
driver
strive
nearcomplet
safeti
expens
patient
health
qualiti
life
may
best
cours
action
patient
clinician
lack
cohes
intern
strategi
blood
donat
screen
press
concern
need
address
furthermor
formal
coordin
continu
riskassess
manag
action
plan
need
develop
deal
constant
potenti
risk
emerg
infect
establish
intern
registri
harmonis
data
collect
nation
registri
dedic
task
forc
may
help
identifi
newli
emerg
pathogen
rapidli
past
improv
pathogen
safeti
bloodplasmaderiv
product
blood
suppli
gener
use
bloodplasmaderiv
product
treatment
bleed
disord
carri
risk
pathogen
transmiss
blood
donat
screen
key
pathogen
hbv
hcv
hiv
caus
agent
syphili
screen
test
conduct
requir
accord
geograph
locat
patient
risk
factor
screen
test
pathogen
may
lack
sensitivityspecif
fals
neg
may
occur
result
residu
pathogen
risk
patient
term
pathogen
safeti
recombin
product
product
minim
exposur
bloodplasmaderiv
protein
consid
pose
lowest
level
risk
patient
research
agenda
region
intern
rate
transfusiontransmit
infect
key
pathogen
emerg
pathogen
safeti
efficaci
bloodplasmaderiv
product
recombin
product
treatment
bleed
disord
